Sugi Predict

Sugi Predict / Compounds / SCHEMBL129095

SCHEMBL129095

SCHEMBL129095

[CH2]c1ccnc(OCC)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 5/20 0.37
▸ GABRA1 P14867 2/20 0.37
▸ GABRG2 P18507 2/20 0.37
▸ GABRB3 P28472 2/20 0.37
▸ GABRA5 P31644 2/20 0.37
▸ GABRA3 P34903 2/20 0.37
▸ GABRP O00591 1/20 0.37
▸ GABRD O14764 1/20 0.37
▸ GABRB1 P18505 1/20 0.37
▸ GABRA2 P47869 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ GABRA4 P48169 1/20 0.37
▸ GABRE P78334 1/20 0.37
▸ GABRA6 Q16445 1/20 0.37
▸ GABRG1 Q8N1C3 1/20 0.37
▸ GABRG3 Q99928 1/20 0.37
▸ GABRQ Q9UN88 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ LOX P28300 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL129039 0.84 GABRP (0.40) ACACBGABRA1GABRG2GABRB3GABRA5
SCHEMBL127714 0.78 — —
SCHEMBL3817033 0.77 NQO1 (0.48) HPGDNQO1MAPTNPC1ALDH1A1
SCHEMBL129096 0.77 UHRF1 (0.48) ACACBGABRA1GABRG2GABRB3GABRA5
SCHEMBL171947 0.77 TP53 (0.48) ACACBGABRA1GABRG2GABRB3GABRA5
SCHEMBL134512 0.76 LOXL2 (0.46) ACACBGABRA1GABRG2GABRB3GABRA5
SCHEMBL164636 0.75 ACACB (0.37) ACACBGABRA1GABRG2GABRB3GABRA5
SCHEMBL30551571 0.75 GABRA1 (0.45) ACACBGABRA1GABRG2GABRB3GABRA5
SCHEMBL13226976 0.75 NOS3 (0.53) ACACBGABRA1GABRG2GABRB3GABRA5
SCHEMBL170306 0.75 MAPT (0.42) ACACBGABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113004278-B Bicyclic heterocycles as FGFR inhibitors 因赛特控股公司 2023-07-21 — — CN claimed
CN-113004278-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2021-06-22 — — CN claimed
CN-107438607-B Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2021-02-05 — — CN claimed
CN-113004278-B Bicyclic heterocycles as FGFR inhibitors 因赛特控股公司 2023-07-21 — — CN disclosed
US-11173162-B2 Bicyclic heterocycles as FGFR4 inhibitors INCYTE CORPORATION (US) 2021-11-16 — — US disclosed
EP-3617205-B1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORP (US) 2021-08-04 — — EP disclosed
CN-113004278-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2021-06-22 — — CN disclosed
CN-107438607-B Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2021-02-05 — — CN disclosed
US-20200306256-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS INCYTE CORPORATION 2020-10-01 — — US disclosed
US-10632126-B2 Bicyclic heterocycles as FGFR4 inhibitors INCYTE CORPORATION (US) 2020-04-28 — — US disclosed
EP-3259269-B9 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORP (US) 2020-03-04 — — EP disclosed
EP-3259269-B1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORP (US) 2019-09-04 — — EP disclosed
US-10251892-B2 Bicyclic heterocycles as FGFR4 inhibitors INCYTE CORPORATION (US) 2019-04-09 — — US disclosed
US-20170290839-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS INCYTE CORPORATION 2017-10-12 — — US disclosed
US-9708318-B2 Bicyclic heterocycles as FGFR4 inhibitors INCYTE CORPORATION (US) 2017-07-18 — — US disclosed
US-20160244449-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS INCYTE CORPORATION 2016-08-25 — — US disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 — — US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 — — EP disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 — — US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306256-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS FGFR4, FGFR3, FGFR1 ACACB 338/4885GABRA1 909/4885GABRG2 595/4885
US-10251892-B2 Bicyclic heterocycles as FGFR4 inhibitors FGFR4, FGFR3, FGFR1 ACACB 439/4885GABRA1 1078/4885GABRG2 515/4885
US-10632126-B2 Bicyclic heterocycles as FGFR4 inhibitors FGFR4, FGFR3, FGFR1 ACACB 439/4885GABRA1 1078/4885GABRG2 515/4885
US-20170290839-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS FGFR4, FGFR3, FGFR1 ACACB 338/4885GABRA1 909/4885GABRG2 595/4885
US-11173162-B2 Bicyclic heterocycles as FGFR4 inhibitors FGFR4, FGFR3, FGFR1 ACACB 439/4885GABRA1 1078/4885GABRG2 515/4885
US-20160244449-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS FGFR4, FGFR3, FGFR1 ACACB 338/4885GABRA1 909/4885GABRG2 595/4885
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 ACACB 185/4885GABRA1 1367/4885GABRG2 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.